The European Biopharmaceutical Enterprises, EBE, is pleased to announce its Board of Directors for the term 2016-2018, following the decisions taken at the EBE and EFPIA (European Federation of Pharmaceutical Industries and Associations) Annual Meetings on 14 to 16 June 2016.

EBE members appointed a 13-strong C-level board headed by Eduardo Bravo, CEO of TiGenix, who previously served as EBE Vice-President. Mr. Bravo has more than twenty-five years of experience in the biopharmaceutical industry. Since 2011, he has been CEO of TiGenix. He was previously CEO of Cellerix and held senior management positions at Sanofi-Aventis, including Vice President for Latin America. Mr. Bravo holds a degree in Business Administration and an MBA (INSEAD). He is also a member of the Executive Committee of the Alliance for Regenerative Medicine (ARM). Mr. Bravo brings invaluable experience from the field of advanced therapies, bridging the gap between the lab and personalised medicines, supported by a thriving innovation ecosystem.

To continue driving the association’s strategic focus on emerging sciences and advanced technologies, Mr. Andrea Chiesi will support Mr Bravo, as Vice-President of EBE. Andrea serves currently as Vice-President of Holostem Advanced Therapies and Director R&D Project Portfolio Management at Chiesi Farmaceutici. Active in the field of advanced therapies, Mr. Chiesi also brings the views of a globally successful, privately owned, mid-sized pharmaceutical company to the EBE leadership. Didier Malherbe, Vice-President of Public Affairs, UCB and Managing Director UCB Belgium, was re-elected as Treasurer of EBE, in recognition of his contribution towards a financially-sustainable EBE.

Newly appointed to the EBE Board of Directors were Nicola Beaucamp, Head of Process Research in Pharma Research & Early Development at Roche, and Michele Antonelli, President of Stallergenes SAS and Executive Vice President, Head of Europe and International at Stallergenes Greer, bringing expertise in process design and diagnostics, and in allergy immunotherapy. Roberto Gradnik, the previous EBE president rejoined the Board as Chief Executive Officer of Ixaltis, a new member of EBE.
“The EBE Board of Directors for 2016 to 2018 harnesses the experience of small, medium and large biopharmaceutical companies in a unique combination. I am delighted to be working with such a dedicated group of senior leaders (full list below) to steer EBE’s initiatives to advance the European innovation ecosystem, and support the translation of emerging sciences into therapeutic solutions for the benefit of patients in Europe,” said Barbara Freischem, Executive Director EBE.

“EBE is in an exciting phase of consolidation, with our cutting-edge technologies driving the biopharmaceutical pipelines towards curing difficult-to-treat conditions and diseases,” stated Eduardo Bravo, President of EBE. “I invite you to explore the work of EBE on our website, for example by watching the discussion at our 2016 Annual Meeting on how the Innovative Medicines Initiative can bring forward the development of advanced therapies.”

EBE Board Composition 2016 – 2018